Global Dendritic Cell Therapy Vaccine Market – Industry Trends and Forecast to 2029

Global Dendritic Cell Therapy Vaccine Market, By Product (CreaVax, Sipuleucel-T, and Others), End-Use (Pediatrics and Adults) – Industry Trends and Forecast to 2029

Market Analysis and Size

Dendritic cells (DCs) are a type of leukocyte that is relatively uncommon. Because of their exceptional ability to deliver antigens to T cells, they have recently been applied to therapeutic cancer vaccinations. In experimental animals, isolated DCs loaded with tumour antigen ex vivo and delivered as a cellular vaccination generate protective and therapeutic anti-tumor immunity.

Data Bridge Market Research analyses that the dendritic cell therapy vaccine market which was USD 8.35 billion in 2021, would rocket up to USD 12.57 billion by 2029, and is expected to undergo a CAGR of 5.25% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation      

Market Definition

Dendritic cells are antigen-presenting cells found in lymphoid organs, their primary role is to activate T cells and display antigens. Antigen display aids in pathogen and microbe recognition by T-cells, allowing for their eradication and identification from the body. These cells aid in the capture and processing of tumor antigens, resulting in the activation of lymphocyte co-stimulatory molecules and the production of cytokines to trigger the immune response.

Dendritic Cell Therapy Vaccine Market Dynamics

Drivers

• Increasing number of cancer rises

The dendritic cell therapy is employed in the identification and treatment of cancer, and as the number of cancer cases rises every day, its use and growth operate as a growth factor. Radiation therapy, chemotherapy, and surgery are common treatments. Dendritic cells are adaptable in nature and can be modified completely depending on the cancer under investigation. This dendritic cell vaccine can be formulated based on the type of tumour in the body, it aids in the treatment of multiple cancers, and it is effective for a variety of goals, and it will act as a market growth factor.

• Rising prevalence of cancer

The commercial success of unique dendritic cell vaccines will be fueled by the rising prevalence of cancer around the world. For instance, In 2018, more than 70000 and 120000 persons are predicted to be diagnosed with renal cell carcinoma in the United States and Europe, respectively, resulting in significant market success for Rocapuldencel-T. In addition, over 1 million new cancer cases are projected in Japan in 2018, fueling the dendritic cell cancer vaccine market in the country.

• Increasing clinical trials activity along with new product launches

The growing discovery of therapy medications in clinical trials, as well as the associated market potential, is revealing new information about the evolution and uniqueness of therapy in the cancer therapeutics industry. In recent years, the number of study theories on therapy has increased dramatically, making it one of the most prolific suppliers to global publications. Because the applications that are related with the market have no restrictions, the whole market research for the therapy is predicted to be an amalgamation of a large amount of information from researchers at the clinical and preclinical level.

Opportunities

Researchers have been drawn to the therapy because of the medications in development and the therapy's capacity to transfer fundamental research into translational research. Because the applications, routes, and healthcare benefits associated with the market are substantial, major biopharmaceutical companies around the world are also getting involved in the overall development of the therapy for cancer patients. Now, with its strong and extensive clinical pipeline, the market for dendritic cell immunotherapy is becoming more adjusted and inclined towards the complete pharmaceutical business, specifically for cancer, resulting in multiple overlapping opportunities for investors, researchers and patients.

Restraints/Challenges

Low availability of vaccines in remote areas and stringent regulatory procedures will act as a restraint, and further challenge the growth in the dendritic cell therapy vaccine market in 2022-2029 forecast period.

This dendritic cell therapy vaccine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the dendritic cell therapy vaccine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Dendritic Cell Therapy Vaccine Market

Covid-19 had a favourable effect on the market. The COVID-19 pandemic is caused by the SARS-CoV-2 virus. Coronavirus first appeared in china and quickly spread to over 200 nations around the world. Despite the fact that the majority of patients are slightly unwell or even asymptomatic, a small percentage of them develop severe pneumonia and become dangerously ill. Understanding the interaction of SARS-CoV-2 with the immune system, as well as the role of defective immune responses in disease progression, will be critical for understanding COVID-19 pathophysiology, risk factors for the worst outcome, and rational design of effective medicines and vaccines. Dendritic cells serve as vital connection between innate and adaptive immunity in the fight against viral infections.

Global Dendritic Cell Therapy Vaccine Market Scope

The dendritic cell therapy vaccine market is segmented on the basis of product type and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• CreaVax
• Sipuleucel-T (Provenge)
• Others

End User

• Pediatrics
• Adults

Dendritic Cell Therapy Vaccine Market Regional Analysis/Insights

The dendritic cell therapy vaccine market is analysed and market size insights and trends are provided by country, product type and end-user as referenced above.

The countries covered in the dendritic cell therapy vaccine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the dendritic cell therapy vaccine market due to the high prevalence of cancer patients and good medical infrastructure in the region.

Asia-Pacific is expected to growing region in the forecast period of 2022 to 2029.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Dendritic Cell Therapy Vaccine Market Share Analysis

The dendritic cell therapy vaccine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to dendritic cell therapy vaccine market.

Some of the major players operating in the dendritic cell therapy vaccine market are:

• 3M (U.S)
• Argos Therapeutics (U.S)
• Batavia Bioservices (Netherlands)
• Bellicum Pharmaceuticals Inc. (U.S)
• JW Creagene (South Korea)
• DanDrit Biotech (U.S)
• DCPrime (Netherlands)
• The Sanpower Group (U.S)
• Elios Therapeutics Inc. (U.S)
• ImmunoCellular Therapeutics Ltd. (U.S)
• Immunicum AB (Sweden)
• Kiromic BioPharma, Inc. (U.S)
• Medigene AG (Germany)
• Merck & Co. Inc. (U.S)
• Northwest Biotherapeutics Inc. (U.S)
• Glaxo plc (U.S)
• Tella Inc. (China)
• Vaxil BioTherapeutics (Canada)